Orrick, Herrington & Sutcliffe LLP
10/22/2025 | Press release | Distributed by Public on 10/22/2025 10:28
Bexorg Completes $23M Series A Bringing Total Funding to $42.5M
Bexorg, a clinical-stage biotech pioneering therapies for central nervous system (CNS) disorders, has completed a $23 million Series A financing, bringing its total funding to $42.5 million, to advance its platform and pipeline of novel therapeutics.
Orrick advised Bexorg on the round, led by Engine Ventures with support from Amplify Partners, Starbloom Capital, Connecticut Innovations and E1 Ventures.
THE COMPANY
Bexorg leverages proprietary technology to accelerate the discovery and development of innovative CNS treatments, aiming to improve outcomes for patients with complex neurological conditions.
THE IMPACT
Proceeds from the financing will enable Bexorg to expand and optimize its AI engine trained on clinically predictive whole-human brain data. The investment will accelerate clinical development and advance CNS discovery and development programs through partners and in-licensed assets, ultimately bringing innovative therapies to patients.
THE TEAM
The team was led by Mark Solakian and Jake Gatof and includes Rozman Lynch and Michelle Dold.
LEARN MORE
- Bexorg Press Release
- Read More Orrick Client Results
Orrick, Herrington & Sutcliffe LLP published this content on October 22, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 22, 2025 at 16:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]